American Society of Hirudotherapy

Smart Library

Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.

Curated knowledge library: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Reference collection: Content is historical, educational, or biographical reference material — not a clinical recommendation.

New to hirudotherapy? Start here

This library indexes the full evidence base. For orientation, begin with the core guides:

Compounds

70

Hirudin

The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Calin

Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Saratin

Anti-platelet adhesion protein blocking collagen-mediated platelet activation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Destabilase

Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Antistasin

Factor Xa inhibitor from the Mexican leech (1987) — used in early animal studies of factor Xa as a target; the DOAC drugs are synthetic and not derived from it.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Decorsin

RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Ornatin

RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hementerin

Direct fibrinogenolytic enzyme — degrades fibrinogen independently of plasmin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Lefaxin

Factor Xa inhibitor with anti-inflammatory properties.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudin-PA

Hirudin variant from Hirudinaria manillensis with distinct kinetics.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirullin P18

Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

LCI (Leech Carboxypeptidase Inhibitor)

Inhibitor of TAFI (thrombin-activatable fibrinolysis inhibitor) — synergizes with hirudin's anticoagulant action.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hementin

Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Antithrombin III binding protein

Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Therostasin

Factor Xa inhibitor from Theromyzon tessulatum — Kunitz-domain analog with novel selectivity profile.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Haemadin

Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Tridegin

Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Destabilase Isopeptidase Activity

Isopeptidase domain of destabilase that cleaves cross-linked fibrin — distinct from lysozyme domain.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Leech Ecotin-like Factor

Trypsin and Factor Xa inhibitor with broad-spectrum serine protease activity.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Saratin-2

Isoform of saratin — collagen-binding anti-platelet protein from Hirudo medicinalis.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hementin-Like Protein (HLP-1)

Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

LAPP-2 (Leech Anti-Platelet Protein, Isoform 2)

Isoform of LAPP — collagen-binding inhibitor of platelet adhesion.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Leech Adhesion-Inhibitor Protein

Salivary protein blocking platelet adhesion to extracellular matrix components.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Theromin

Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Saratin-3

Collagen-binding antiplatelet variant from the Hirudo medicinalis sialotranscriptome — paralog of saratin and saratin-2.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudonin

Small thrombin-inhibitor peptide identified in the Hirudo medicinalis salivary transcriptome — truncated hirudin-family analog.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Gelin

Antiplatelet peptide identified in leech salivary transcriptome — inhibits platelet aggregation in vitro.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Gelin-2

Paralog of gelin identified in the Hirudo medicinalis sialotranscriptome — putative antiplatelet variant.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

LAPP (Leech Anti-Platelet Protein)

Antiplatelet protein from Haementeria officinalis — vWF-A1 / collagen-binding inhibitor with reported antithrombotic activity in preclinical models.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Gnathobdellin

Salivary protein family from Asian medicinal leeches Hirudo nipponia and Hirudo japonica — putative anticoagulant.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Destabilase-3

Paralog variant of destabilase identified in Hirudo medicinalis sialotranscriptome — isopeptidase/lysozyme bifunctional family member.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Leech Platelet Aggregation Inhibitor 2

Secondary RGD-motif platelet-aggregation inhibitor reported from the leech salivary secretome — family member with decorsin / ornatin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Cysteine-Rich Anticoagulant (CRA)

Novel cysteine-rich recombinant anticoagulant from Hirudo medicinalis saliva — strong anticoagulant activity in clotting assays; C-terminal motif governs membrane affinity.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Fenestrin-1

RGD-motif salivary peptide from the African medicinal leech Asiaticobdella fenestrata, proposed as a platelet aggregation inhibitor; its target is not yet confirmed.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Fenestrin-2

Second RGD-motif salivary peptide from Asiaticobdella fenestrata (Schulz 2025 sialotranscriptome), proposed as a platelet aggregation inhibitor; its target is not yet confirmed.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Asiaticobdella Hirudin-1

Putative hirudin-like factor with RGD motif from African medicinal leech — dual thrombin-inhibitor / integrin-binder mechanism unique to A. fenestrata.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

WP-DLRWM

Five-residue intestinally absorbable anticoagulant peptide from Whitmania pigra trypsin hydrolysate — Fang 2025 peptidomics + everted-gut-sac validation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Haemadin-Interrupta-1

Bivalent exosite-II thrombin inhibitor from the Malayan land leech Haemadipsa interrupta — Müller 2024 transcriptome identification + recombinant functional characterization.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Haemadipsa Oligomeric Decorsin

First oligomeric decorsin-class platelet aggregation inhibitor identified in a haemadipsid leech (Müller 2024) — weak inhibitor in functional assays.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

WpDestabilase

Whitmania pigra destabilase ortholog (Huang 2026) — isopeptidase + clot-destabilizing activity; C-terminal IPATETTTEI deletion enhances isopeptidase activity.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

HmDestabilase

Hirudinaria manillensis destabilase / i-type lysozyme (Gao 2025) — isopeptidase + lysozyme activity, salivary-gland-upregulated on blood feeding.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudin P6

Tyrosine-sulfated, O-glycosylated hirudin variant from Hirudo medicinalis — Maxwell 2023 chemical-synthesis study reveals sulfation increases thrombin inhibition ~10-fold.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudo tianjinensis Decorsin

Monomeric + oligomeric decorsin paralogs identified in Asian medicinal leech H. tianjinensis (Kalatehjari 2026) — first recombinant characterization as platelet aggregation inhibitors.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudo tianjinensis Multimeric Hirudin

Multi-domain hirudin superfamily proteins from H. tianjinensis (Kalatehjari 2026) — two-or-more central globular domains per molecule.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudo nipponia Hirudin

Salivary-gland hirudin variant from H. nipponia (Shi 2023) — recombinant Pichia pastoris expression with documented antithrombin activity (14,000 ATU/mL).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Whitmania pigra Hirudin

First documented hirudin / hirudin-like factor family in a non-hematophagous leech — Müller 2022 thrombin-inhibitory characterization of W. pigra salivary transcripts.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Bdellin-HM-2

Non-classical Kazal-type protease inhibitor from Hirudinaria manillensis — prolongs aPTT without inhibiting trypsin, thrombin, FXa, FXIIa, or kallikrein (Cheng 2019).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Tandem-Hirudin (TH)

Bivalent tandem-domain hirudin homolog from Hirudinaria manillensis — two globular domains without C-terminal tail; structurally distinct from kissing-bug / tick analogs (Lukas 2022).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Phospho-Hirudin (pY63 variant)

Synthetic phosphotyrosine-63 hirudin analog with higher thrombin affinity than native sulfo-hirudin — Volkova 2023 steered-MD + in vitro plasma assay.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Leech Antistasin-Homolog Anticoagulant

Novel Hirudo medicinalis salivary protein (28% identity to antistasin) with stronger aPTT inhibition than hirudin at equimolar concentration — Manuvera 2024.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Showing first 50 of 70. Refine filters to narrow results.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Smart Library — Faceted Search Across All Registries | ASH